188751-44-2

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 118684-31-4 tert-butyl N-[3-(hydroxymethyl)phenyl]carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1877-77-6 3-aminobenzenemethanol 
• 205318-52-1 tert-butyl 3-(aminomethyl)phenylcarbamate 

Downstream Products

• 1431958-42-7 C₂₅H₂₁N₅O₂ 
• 1431958-43-8 C₂₂H₂₁N₅O₂ 
• 1431958-44-9 C₂₀H₁₉N₅O₂ 
• 1431958-45-0 C₂₆H₂₃N₅O₃ 
• 675106-71-5 Boc-mAZ-pTyr(MeSATE)2-(α-Me)pTyr(MeSATE)2-Asn-NH2 

Relevant academic research and scientific papers

Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2- SH2 domain

The observation that anthranilic acid as N-terminal group produces a dramatic increase of the binding affinity of the phosphopeptide sequence Glu- pTyr-Ile-Asn for the Grb2-SH2 domain was rationalized by molecular modeling. The model, which invokes a stac

CHEMICAL COMPOUNDS

The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b- and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS

The present invention relates to the new use of 2,4-diamino-3-hydroxycarboxylic acids of formula (I), in which A and B independently represent a bond or an unsubstituted or substituted amino acyl moiety; R1 represents hydrogen; an amino protecting group;